JP2021100937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021100937A5 JP2021100937A5 JP2021031431A JP2021031431A JP2021100937A5 JP 2021100937 A5 JP2021100937 A5 JP 2021100937A5 JP 2021031431 A JP2021031431 A JP 2021031431A JP 2021031431 A JP2021031431 A JP 2021031431A JP 2021100937 A5 JP2021100937 A5 JP 2021100937A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- equation
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16150624.1 | 2016-01-08 | ||
| EP16150624 | 2016-01-08 | ||
| EP16179286 | 2016-07-13 | ||
| EP16179286.6 | 2016-07-13 | ||
| EP16191458.5 | 2016-09-29 | ||
| EP16191458 | 2016-09-29 | ||
| JP2018535304A JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535304A Division JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021100937A JP2021100937A (ja) | 2021-07-08 |
| JP2021100937A5 true JP2021100937A5 (enExample) | 2021-08-26 |
| JP6951597B2 JP6951597B2 (ja) | 2021-10-20 |
Family
ID=57838356
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535304A Active JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2021031431A Active JP6951597B2 (ja) | 2016-01-08 | 2021-03-01 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2023147381A Active JP7692454B2 (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535304A Active JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2023147381A Active JP7692454B2 (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US10835578B2 (enExample) |
| EP (1) | EP3400020A1 (enExample) |
| JP (4) | JP7051686B2 (enExample) |
| AU (2) | AU2017205268B2 (enExample) |
| CA (1) | CA3007976C (enExample) |
| MX (1) | MX2018008061A (enExample) |
| WO (1) | WO2017118693A1 (enExample) |
| ZA (1) | ZA201804414B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| EP4162955A1 (en) | 2016-01-08 | 2023-04-12 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| US11224661B2 (en) | 2016-01-08 | 2022-01-18 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with increased NEP stability |
| US11389511B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| US11311604B2 (en) * | 2016-01-08 | 2022-04-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
| NZ751746A (en) | 2016-09-29 | 2023-06-30 | Ascendis Pharma Growth Disorders As | Combination therapy with controlled-release cnp agonists |
| AU2018231832A1 (en) | 2017-03-10 | 2019-08-08 | Quiapeg Pharmaceuticals Ab | Releasable conjugates |
| BR112020019639A2 (pt) * | 2018-03-28 | 2021-01-05 | Ascendis Pharma Oncology Division A/S | Conjugados de il-2 |
| EP3849660A1 (en) | 2018-09-12 | 2021-07-21 | QuiaPEG Pharmaceuticals AB | Releasable glp-1 conjugates |
| CN113423384B (zh) * | 2019-02-11 | 2024-01-05 | 阿森迪斯药物生长障碍股份有限公司 | Cnp缀合物的干燥药物制剂 |
| IL298642A (en) | 2020-06-03 | 2023-01-01 | Ascendis Pharma Oncology Div A/S | il-2 sequences and uses thereof |
| AU2021288045A1 (en) * | 2020-06-12 | 2023-02-09 | Pharmain Corporation | C-type natriuretic peptides and methods thereof in treating cancer |
| WO2023110758A1 (en) * | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| CA3249311A1 (en) * | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS |
| KR102866559B1 (ko) | 2022-11-02 | 2025-10-02 | 노보 노르디스크 에이/에스 | Cnp 화합물 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| CA2345414A1 (en) | 1998-09-28 | 2000-04-06 | Santen Pharmaceutical Co., Ltd. | Eyedrops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as active ingredient |
| EP2305312B1 (en) | 2001-10-10 | 2015-03-04 | ratiopharm GmbH | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| US8596542B2 (en) * | 2002-06-04 | 2013-12-03 | Hand Held Products, Inc. | Apparatus operative for capture of image data |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP1569683B1 (en) * | 2002-11-26 | 2010-03-03 | Biocon Limited | Modified natriuretic compounds, conjugates, and uses thereof |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| CA2843439A1 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
| JP4950022B2 (ja) | 2004-03-23 | 2012-06-13 | コンプレックス バイオシステムズ ゲーエムベーハー | 自壊性リンカーを有する高分子プロドラッグ |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| BRPI0716228A2 (pt) | 2006-09-08 | 2013-10-15 | Mayo Foundation | Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora |
| CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
| CN101553206B (zh) | 2006-11-09 | 2012-11-21 | 爱尔康研究有限公司 | 用于药物递送的水不溶性聚合物基质 |
| AU2008242805B2 (en) * | 2007-04-20 | 2012-01-19 | Shell Internationale Research Maatschappij B.V. | In situ heat treatment of a tar sands formation after drive process treatment |
| KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| HRP20110368T1 (hr) | 2007-06-21 | 2011-06-30 | Technische Universitt Mnchen | Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro |
| EP2175878A4 (en) | 2007-07-11 | 2014-12-03 | Belrose Pharma Inc | POLYMER DRUG DISPENSING SYSTEM WITH A MULTIPLE SUBSTITUTED AROMATIC PART |
| AU2008326327A1 (en) | 2007-11-21 | 2009-05-28 | Biomarin Pharmaceutical Inc. | Variants of C-type natriuretic peptide |
| CN101980725B (zh) * | 2008-02-01 | 2013-06-12 | 阿森迪斯药物股份有限公司 | 包含可自裂解的连接体的前药 |
| EP2288261A4 (en) | 2008-05-23 | 2013-09-25 | Enzon Pharmaceuticals Inc | POLYMER SYSTEMS CONTAINING INTRA-CELLULAR RELEASE DISULFID LINKERS FOR THE DISPOSAL OF OLIGONUCLEOTIDES |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| EP2334334A1 (en) | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| SI2393828T1 (sl) | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
| PE20120792A1 (es) | 2009-05-20 | 2012-07-27 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| US9173953B2 (en) | 2009-07-31 | 2015-11-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| EP3372617B1 (en) | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| DK2566334T3 (en) | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
| JP5977229B2 (ja) | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| AU2011254564B2 (en) | 2010-05-21 | 2014-03-27 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| WO2013024048A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| JP6092867B2 (ja) | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー／エス | 担体連結しているトレプロスチニルプロドラッグ |
| US20140249093A1 (en) | 2011-08-12 | 2014-09-04 | Ascendis Pharma A/S | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages |
| US20140323402A1 (en) | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
| EP2741779A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| CN104379171A (zh) | 2012-04-25 | 2015-02-25 | 第一三共株式会社 | 骨修复促进剂 |
| EP2841109A1 (en) | 2012-04-25 | 2015-03-04 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| JPWO2015129812A1 (ja) | 2014-02-27 | 2017-03-30 | 第一三共株式会社 | ステロイド剤投与で誘発される成長障害に対する医薬 |
| AU2015299055C1 (en) | 2014-08-06 | 2021-05-06 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| MY199991A (en) * | 2015-01-09 | 2023-12-02 | Ascendis Pharma Growth Disorders As | Cnp prodrugs |
| CA3007315A1 (en) | 2015-12-08 | 2017-06-15 | Biomarin Pharmaceutical Inc. | Use of c-type natriuretic peptide variants to treat osteoarthritis |
| US11224661B2 (en) | 2016-01-08 | 2022-01-18 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with increased NEP stability |
| US11389511B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| US11311604B2 (en) | 2016-01-08 | 2022-04-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| EP4162955A1 (en) | 2016-01-08 | 2023-04-12 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| NZ751746A (en) * | 2016-09-29 | 2023-06-30 | Ascendis Pharma Growth Disorders As | Combination therapy with controlled-release cnp agonists |
| CN113423384B (zh) | 2019-02-11 | 2024-01-05 | 阿森迪斯药物生长障碍股份有限公司 | Cnp缀合物的干燥药物制剂 |
-
2017
- 2017-01-05 CA CA3007976A patent/CA3007976C/en active Active
- 2017-01-05 MX MX2018008061A patent/MX2018008061A/es unknown
- 2017-01-05 EP EP17700618.6A patent/EP3400020A1/en active Pending
- 2017-01-05 JP JP2018535304A patent/JP7051686B2/ja active Active
- 2017-01-05 US US16/067,057 patent/US10835578B2/en active Active
- 2017-01-05 WO PCT/EP2017/050201 patent/WO2017118693A1/en not_active Ceased
- 2017-01-05 AU AU2017205268A patent/AU2017205268B2/en active Active
-
2018
- 2018-07-02 ZA ZA2018/04414A patent/ZA201804414B/en unknown
-
2020
- 2020-08-27 US US17/005,272 patent/US20210077584A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,561 patent/US11154593B2/en active Active
- 2021-03-01 JP JP2021031431A patent/JP6951597B2/ja active Active
- 2021-11-15 US US17/526,481 patent/US20220296682A1/en not_active Abandoned
-
2022
- 2022-03-01 AU AU2022201416A patent/AU2022201416B2/en active Active
- 2022-03-30 JP JP2022054845A patent/JP7350123B2/ja active Active
-
2023
- 2023-09-12 JP JP2023147381A patent/JP7692454B2/ja active Active
-
2024
- 2024-01-08 US US18/407,324 patent/US20240316153A1/en not_active Abandoned
- 2024-12-19 US US18/986,709 patent/US20250127859A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021100937A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| JP2004509061A5 (enExample) | ||
| JP2007501809A5 (enExample) | ||
| JP2006526590A5 (enExample) | ||
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2020507589A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| EP4628100A3 (en) | Anti-viral compounds and methods for administration thereof | |
| JP2006523216A5 (enExample) | ||
| JP2005532332A5 (enExample) | ||
| JP2004504406A5 (enExample) | ||
| JP2004505095A5 (enExample) | ||
| JP2005508337A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2022095872A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2006528152A5 (enExample) | ||
| JP2021505540A5 (enExample) | ||
| JP2005526833A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| JP2011518176A5 (enExample) | ||
| JP2010500284A5 (enExample) | ||
| JP2025118775A5 (enExample) |